Forxiga® - HFpEF
10mg | Tablets
TerugBetaalRegeling Forxiga® (dapagliflozin) 10 mg for patients with symptomatic chronic heart failure with a LVEF ≥ 40% (HFmrEF & HFpEF).
TBR Nederland started a TerugBetaalRegeling from 13 February 2023 for Forxiga® (dapagliflozin) 10 mg for heart failure patients with a LVEF ≥ 40% (HFmrEF & HFpEF), without diabetes type 2 and/or chronic kidney disease. The end date for this TBR for this patient group has not yet been determined.
The TerugBetaalRegeling applies for adults (>18y) with heart failure with a LVEF ≥40% (HFmrEF & HFpEF), with exceptions of patients who also have:
- Chronic kidney disease and/or;
- Diabetes mellitus type 2 who:
o Use metformin and/or SU or
o Previous experienced a cardiovascular event
NB: for the excluded group GVS reimbursement is already available. See the current GVS reimbursement in the ‘reimbursement overview’ and in the digital ‘reimbursement guide’.
For a complete reimbursement overview of Forxiga® (dapagliflozin) 10 mg, click here
For a digital reimbursement guide of Forxiga® (dapagliflozine) 10 mg, click here.
Dose | Forxiga® 10mg |
Type | Tablets |
Active ingredient | DAPAGLIFLOZINE |
The full cost of Forxiga® (dapagliflozine) 10 mg is reimbursed through TBR Nederland.
You can only send in your expense with an issue date from February 13, 2023. For the Reimbursement Scheme of this medicine no closing date has been determined yet.
Patients and pharamcists can claim online and will receive the reimbursement within 5 working days.
Patients can claim by post and will receive their reimbursement within 15 working days.
Please mail the Claim Form and attachments to:
TBR Nederland
Postbus 8011
1180 LA Amstelveen
If you need any assistance please read our Frequently Asked Questions.
Still does not work? Please contact our Servicedesk via e-mail or call the Forxiga® service-number 088 - 0026740
Quickly check the maximum contribution you have to pay for your medicine